Mu-opioid antagonist (short-acting)

Plain-language summaryIntrigue 64 / 100

Naloxone, sold as Narcan, is the standard reversal agent for opioid overdose. It competitively binds and displaces opioids from the mu-opioid receptor with high affinity, restoring breathing within minutes when administered intramuscularly or as an intranasal spray. Public health programs have made intranasal naloxone available without prescription in pharmacies and from harm-reduction organizations across most of the US, and bystander administration is credited with thousands of overdose reversals annually. The short half-life means re-dosing may be required for long-acting opioids like methadone or fentanyl analogs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

50/100

The canonical opioid antagonist probe; indispensable in its niche but far from a novel research target

Look, naloxone isnt a research target. It’s a research tool. That distinction matters a lot when you’re trying to explain a score of 50, which might seem high for a compound that scores 12 on novelty and 22 on mechanism promise. The thing is, those two axes tell the truth about where naloxone sits right now: it’s a 1971 FDA approval with a completely understood competitive antagonism profile at mu-opioid receptors (Ki approximately 1 nM), and nobody in the field is surprised by any of that. The pharmacology is textbook. The mechanism is single-receptor competitive antagonism, about as mechanistically unexciting as it gets for a research library context.

So why does it score 50 at all? Because evidence quality and translational signal are very real, and bench value is genuinely high. As the canonical short-acting, reversible mu-opioid antagonist, naloxone is what you reach for when you want to attribute an effect to opioid receptor activation. You can’t do serious opioid pharmacology without it. In animal behavioral models, in ex vivo receptor binding, in cell culture signaling studies, naloxone is the probe that closes the loop. There’s a reason every paper on endogenous opioids, opioid-mediated analgesia, or itch involves a naloxone blockade condition. It’s not doing anything exciting on its own; it’s the negative control that makes everything else interpretable.

The evidence base is essentially unimpeachable. FDA approved since 1971. Decades of replicated clinical data on reversal efficacy. The intranasal 4 mg formulation has generated real public health outcome data, and the overdose reversal pharmacokinetics are thoroughly characterized across parenteral and mucosal routes. You’re not going to find an evidence-quality problem here. Translational signal similarly scores high because the clinical effect is binary and unambiguous. That’s about as clean a human signal as this field produces.

What we don’t love is the novelty situation. There’s essentially no fresh angle here for a general-purpose research program. Some investigators are poking at ultra-low-dose naloxone in paradoxical opioid sensitization models, and the toll-like receptor 4 story (the non-stereoselective TLR4 binding that the (+)-naloxone isomer isolates) is genuinely interesting mechanistic territory, but that angle hasnt produced clinical traction and remains a niche debate. The low-dose naltrexone literature is adjacent but uses a different compound with a different half-life and a different evidence trajectory.

We think naloxone belongs in the library as a reference compound: the thing you want well-documented and accessible for any research program that touches opioid receptor modulation. Its score reflects exactly what it is, high value in a specific and narrow research context, low value as a forward-looking research target. The 50 is earned by half the formula, and the other half is where it tells on itself.

Novelty: 12
Mechanism promise: 22
In-category differentiation: 52
Evidence quality: 88
Translational signal: 85
Research bench value: 72

Rationale Naloxone earns its 50 from very high evidence quality and translational signal as a 55-year FDA-approved clinical compound, offset by essentially zero novelty and unremarkable single-receptor mechanism; its library value is as the reference mu-antagonist probe for opioid receptor pharmacology, not as a forward-looking research target.

Mu-opioid antagonist (short-acting)

A short-acting mu-opioid antagonist; the standard reversal agent for opioid overdose.

Abstract

Naloxone ((5alpha)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; CAS 465-65-6; molecular formula C19H21NO4; molecular weight 327.37) is a short-acting mu-opioid antagonist approved by the FDA in 1971 (Narcan). The compound is a competitive antagonist at mu, kappa, and delta opioid receptors with preferential mu affinity (Ki approximately 1 nM). Unlike naltrexone, oral bioavailability is poor (less than 5 percent), restricting use to parenteral or intranasal administration. Plasma half-life is approximately 1 to 2 hours, shorter than most opioid agonists, requiring multiple doses or infusion in opioid overdose reversal where the half-life of the offending opioid exceeds naloxone’s. The intranasal formulation (Narcan nasal spray, 4 mg) is widely available and has driven the modern public health response to the opioid overdose epidemic. Approved indications: opioid overdose reversal, postoperative opioid reversal, opioid-induced constipation (IV form alvimopan, methylnaltrexone for that latter). Used as the canonical mu-opioid antagonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-352Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Mu-opioid antagonist (short-acting)

Naloxone

Abstract

Read the full monograph